The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11)

Molecular Pharmacology

Volumn 56, Issue 6, 1999, Pages 1346-1353

  Dodds, Helen M ^a   Rivory, Laurent P ^b,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c University of Sydney   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; IRINOTECAN; NEOSTIGMINE; PROPIDIUM IODIDE; TACRINE;

ARTICLE; BINDING SITE; CHOLINESTERASE INHIBITION; COMPETITIVE INHIBITION; DEACYLATION; DRUG INDUCED DISEASE; DRUG MECHANISM; ENZYME INACTIVATION; HUMAN; HUMAN CELL; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL;

EID: 0032731703     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.56.6.1346     Document Type: Article

References (37)

1. Akimoto K, Kawai A and Ohya K (1994) Kinetic studies of the hydrolysis and lactonization of camptothecin and its derivatives, CPT-11 and SN-38, in aqueous solution. Chem Pharm Bull 42:2135-2138.
2. Al-Jafari AA, Kamal MA and Duhaiman AS (1995) The mode of inhibition of human erythrocyte membrane-bound acetylcholinesterase by cisplatin in vitro. J Enzyme Inhibition 8:281-289.
3. Ariel N, Ordentlich A, Barak D, Bino T, Velan B and Shafferman A (1998) The "aromatic patch" of three proximal residues in the human acetylcholinesterase active centre allows for versatile interaction modes with inhibitors. Biochem J 335:95-102.
4. Berman HA and Leonard K (1992) Interaction of tetrahydroaminoacridine with acetylcholinesterase and butyrylcholinesterase. Mol Pharmacol 41:412-418.
5. Dawson RM (1990) Reversibility of the inhibition of acetylcholinesterase by tacrine. Neurosci Lett 118:85-87.
6. de Forni M, Bugat R, Chabot GG, Culine S, Extra JM, Gouyette A, Madelaine I, Many ME and Mathieu-Boue A (1994) Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54:4347-4354.
7. Dixon M and Webb EC (1979) Enzyme inhibition and activation, in Enzymes (Dixon M, Webb EC, Thorne CJR and Tipton KF eds) pp 337-338, Academic Press, New York.
8. Dodds HM and Rivory LP (1998) The mechanism of the inhibition of acetylcholinesterases by irinotecan (CPT-11) - A lead in explaining the cholinergic toxicity of CPT-11 and its time-course (Abstract). Proc Am Assoc Cancer Res 39:327.
9. Ellman GL, Courtney KD, Andres VJr and Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95.
10. Froede HC and Wilson IB (1984) Direct determination of acetyl-enzyme intermediate in the acetylcholinesterase-catalysed hydrolysis of acetylcholine and acetylthiocholine. J Biol Chem 259:11010-11013.
11. Galli A, Mori F, Gori F and Lucherini M (1992) In vitro protection of acetylcholinesterase and butyrylcholinesterase by tetrahydroaminoacridine. Comparison with physostigmine. Biochem Pharmacol 43:2427-2433.
12. Galli A, Ranaudo E, Giannini L and Costagli C (1996) Reversible inhibition of cholinesterases by opiods: Possible pharmacological consequences. J Pharm Pharmacol 48:1164-1168.
13. Gandia D, Abigerges D, Armand J-P, Chabot G, Da Costa L, De Forni M, Mathieu-Boue A and Herait P (1993) CPT-11 induced cholinergic effects in cancer patients (letter). J Clin Oncol 11:196-197.
14. Gracon SI, Knapp MJ, Berghoff WC, Pierce M, De Jong R, Lobbestael SJ, Symons J, Dombey SL, Luscombe FA and Kraemer D (1998) Safety of tacrine: Clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis Assoc Disord 12:93-101.
15. Harel M, Sussman JL, Krejci E, Bon S, Chanal P, Massoulie J and Silman I (1992) Conversion of acetylcholinesterase to butyrylcholinesterase: Modeling and mutagenesis. Proc Natl Acad Sci USA 89:10827-10831.
16. Hasan FB, Elkind JL, Cohen SG and Cohen JB (1981) Cationic and uncharged substrates and reversible inhibitors in hydrolysis by acetylcholinesterase (EC 3.1.1.7). The trimethyl subsite. J Biol Chem 256:7781-7785.
17. Heilbronn E (1961) Inhibition of cholinesterases by tetrahydroaminoacridine. Acta Chem Scand 16:1386-1390.
18. Kaneda N and Yokokura T (1990) Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res 50:1721-1725.
19. Kawato Y, Sekiguchi M, Akahane K, Tsutomi Y, Hirota Y, Kuga H, Suzuki W, Hakusui H and Sato K (1993) Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats. J Pharm Pharmacol 45:444-448.
20. Ordentlich A, Barak D, Kronman C, Flashner Y, Leitner M, Segall Y, Ariel N, Cohen S, Velan B and Shafferman A (1993) Dissection of the human acetylcholinesterase active center determinants of substrate specificity. J Biol Chem 268:17083-17095.
21. Quinn DM (1987) Acetylcholinesterase: Enzyme structure, reaction dynamics, and virtual transition states. Chem Rev 87:955-979.
22. Riddles PW, Blakeley RL and Zerner B (1979) Ellman's reagent, 5,5′-dithiobis(2-nitrobenzoic acid): A reexamination. Anal Biochem 94:75-81.
23. Rivory LP, Bowles MR, Robert J and Pond SM (1996a) Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 52:1103-1111.
24. Rivory LP, Chatelut E, Canal P, Mathieu-Boué and Robert J (1994) Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res 64:6330-6333.
25. Rivory LP, Riou J-F, Haaz M-C, Sable S, Vuilhorgne M, Commercon A, Pond SM and Robert J (1996b) Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 56:3689-3694.
26. Rivory LP and Robert J (1994) Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J Chromatogr B 661:133-141.
27. Rothenberg ML (1996) CPT-11: An original spectrum of clinical activity. Semin Oncol 23:21-26.
28. Rothenberg ML, Kuhn JG, Burns H 3d, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI et al. (1993) Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204.
29. Shafferman A, Velan B, Ordentlich A, Kronman C, Grosfeld H, Leitner M, Flashner Y, Cohen S, Barak D and Ariel N (1992) Substrate inhibition of acetylcholinesterase: Residues affecting signal transduction from the surface to the catalytic center. EMBO J 11:3561-3568.
30. Sussman JL, Harel M and Silman I (1993) Three-dimensional structure of acetylcholinesterase and of its complexes with anticholinesterase drugs. Chem Biol Interact 87:187-197.
31. Szegletes T, Mallender WD and Rosenberry T (1998) Nonequilibrium analysis alters the mechanistic interpretation of inhibition of acetylcholinesterase by peripheral site ligands. Biochemistry 37:4206-4216.
32. Taylor P (1980) in Pharmacological Basis of Therapeutics (Goodman Gilman A, Goodman LS and Gilman A eds) pp 100-119, MacMillan, New York.
33. Taylor P, Lwebuga-Mukasa J, Lappi S and Rademacher J (1974) Propidium - A fluorescence probe for a peripheral anionic site on acetylcholinesterase. Mol Pharmacol 10:703-708.
34. Wilson IB and Cabib E (1956) Acetylcholinesterase: Enthalpies and entropies of activation. J Am Chem Soc 78:202-207.
35. Wilson IB and Harrison MA (1961) Turnover number of acetylcholinesterase. J Biol Chem 236:2292-2295.
36. Wu CC and Yang JT (1988) Tacrine protection of acetylcholinesterase from inactivation by disopropylfluorophosphate: A circular dichroism study. Mol Pharmacol 35:85-92.
37. Xie W, Altamirano CV, Bartels CF, Speirs RJ, Cashman JR and Lockridge O (1999) An improved cocaine hydrolase: The A328Y mutant of human butyrylcholinesterase is 4-fold more efficient. Mol Pharmacol 55:83-91.